SREBF1 and fatty liver disease: The main underlying mechanisms by which soy isoflavone is capable of alleviating hepatic steatosis are decreasing the level of sterol regulatory element binding protein-1c (SREBP-1c) and the rate of lipogenesis by fatty acid synthase (FAS) and inducing the expression of peroxisome proliferator activated receptor (PPAR) α to stimulate the oxidation of fatty acids14.